Yongchun Yu

Dr. Yongchun Yu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2015 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
NZNi Zhen
Ni Zhen
QYQingyuan Yang
Qingyuan Yang
QWQiong Wu
Qiong Wu
XZXinyi Zhu
Xinyi Zhu
YWYue Wang
Yue Wang
YYYongchun Yu
Yongchun Yu

2 February 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
QYQingyuan Yang
Qingyuan Yang
WLWanrun Lin
Wanrun Lin
ZLZhiwei Liu
Zhiwei Liu
JZJiabei Zhu
Jiabei Zhu
NHNan Huang
Nan Huang
YYYongchun Yu
Yongchun Yu
Esophageal squamous cell carcinoma (ESCC) is the most popular pathology of esophageal cancer (EC) in China, especially in Henan province, mid-east of China. Presently, targeting DNA damage repair (DDR) factors is a promising approach for cancer therapy. Our group has been focusing on exploring the DDR factors overexpressed in ESCC tissues to provide potential targets for therapies for many years. RAP80/UIMC1 (ubiquitin interaction motif containing 1), one of those DDR factors we tested, was highly overexpressed in ESCC tissues compared with adjacent normal tissues. Moreover, the RAP80 mRNA level was validated to be an independent prognosis biomarker for the overall survival time of ESCC patients. The following biological assays revealed that it promoted cell proliferation both in vitro and in vivo, inhibited cell apoptosis at both early and late stages, and participated in G2/M checkpoint regulation. Even though studies have reported that ATM phosphorylates RAP80 at different serine sites upon DNA damage, the reversal regulation of RAP80 on the activity of ATM has never been investigated. In the study, mechanism explorations revealed that RAP80 positively regulated the ATM activity via proteasome–ubiquitination pathway to promote the transition of G2/M phase in cell cycle. By examining a number of E3 ubiquitination ligases (Ub) and deubiquitination (DUb) enzymes, we found that RAP80 positively regulated the stability of USP13 to promote cell proliferation of EC cells. Moreover, inhibition of RAP80 greatly sensitized EC cells to ATM inhibitor KU-55933, triggering a potential combination of RAP80 inhibitors and ATM inhibitors to enhance the therapeutic efficiency of ESCC patients for the clinicians.